| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.3 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.3 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.032 | 0.3 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.064 | 0.3 |